- Open Access
The cerebellar phenotype of Charcot-Marie-Tooth neuropathy type 4C
Cerebellum & Ataxias volume 6, Article number: 9 (2019)
Friedreich ataxia (FRDA) is the most common familial ataxia syndrome in Central and Southern Europe but rare in Scandinavia. Biallelic mutations in SH3 domain and tetratricopeptide repeats 2 (SH3TC2) cause Charcot-Marie-Tooth disease type 4C (CMT4C), one of the most common autosomal recessive polyneuropathies associated with early onset, slow disease progression and scoliosis. Beyond nystagmus reported in some patients, neither ataxia nor cerebellar atrophy has been documented as part of the CMT4C phenotype.
Here we describe a single centre CMT4C cohort. All patients underwent a comprehensive characterization that included physical examination, neurophysiological studies, neuroimaging and genetic testing. In a patient with cerebellar features, an evaluation of the vestibular system was performed.
All five patients in this cohort harbored the R954X mutation in SH3TC2 suggesting a founder effect. Two patients had been diagnosed as FRDA. One of them, an 80-year-old woman had onset of unsteadiness during childhood leading to gradual loss of mobility. She also had scoliosis and hearing loss. On examination she had generalized muscle atrophy, leg flaccidity, pes cavus, facial myokymia, limb dysmetria, dysarthria and gaze-evoked nystagmus. She exhibited bilateral vestibular areflexia. Neuroimaging demonstrated atrophy in the frontoparietal regions and cerebellar hemispheres.
CMTC4A may present with a cerebellar phenotype and mimic a flaccid-ataxic form of FRDA. Absence of cardiomyopathy or endocrine abnormalities and lack of pathological dentate iron accumulation in CMT4C distinguish it from FRDA.
Friedreich ataxia (FRDA) is the most common autosomal recessive ataxia in Western Europe, the Middle East and Northern Africa (1 in 40,000) whereas Charcot-Marie-Tooth type 4C (CMT4C) is one of the most prevalent (18%) type of autosomal recessive CMT . CMT4C is caused by biallelic mutations in the SH3 domain and tetratricopeptide repeats 2 (SH3TC2) and has been associated with a heterogeneous clinical presentation [1,2,3]. Some clinical features of FRDA and CMT4C overlap, with both conditions featuring polyneuropathy and scoliosis. We reviewed a local cohort of 5 patients with CMT4C and suggest that (a) cerebellar signs associated with cerebellar atrophy may be considered within the phenotypic spectrum of CMT4C and (b) its early stages can mimic a “flaccid-ataxic” form of FRDA with slower progression, milder cerebellar ataxia and prominent leg flaccidity (due to severe demyelinating polyneuropathy rather than sensory ganglionopathy). In addition, our cases include trigeminal nerve enlargement and frontoparietal atrophy which are novel neuroimaging abnormalities in CMT4C.
Patients and methods
This study was approved by the local ethics committee in Stockholm; patients provided oral and written consent. Five unrelated CMT4C patients were evaluated using standard motor scales and peripheral nerve conduction studies. Validated scales used included the functional ataxia staging score of overall mobility (subscore of Friedreich’s Ataxia Rating Scale-FARS), the Scale for the Assessment and Rating of Ataxia (SARA) and a composite subscale of the CMT Neuropathy Score (version 2) based on symptoms and signs (CMTES) [4,5,6]. All patients underwent also neuroimaging and targeted gene panel analyses; one patient was investigated with mass sequencing (patient 5 in Table 1). Briefly, genomic DNA from patient 5 was subjected to massive parallel sequencing with whole genome sequencing. The sequencing and primary filtering of variants were performed at Clinical genomics, SciLife, Solna, Sweden. Sequence data was mapped to reference sequence [GRCh37/UCSChg19], and 99% achieved at least 20x coverage. Identified sequence variants were analyzed and filtered using designated software (SCOUT, Clinical Genomics, SciLife Solna). Known genes associated with ataxia and neuromuscular disorders were analyzed. Sequences in exons and exon/intron boundaries, and variants with population frequencies < 0.01 were interpreted.
The vestibular function was documented on a patient with cerebellar features (patient 5) with bithermal caloric test according to Fitzgerald-Hallpike, video head impulse test (vHIT) and with cervical vestibular evoked myogenic potentials (cVEMP) evoked by air conducted stimuli . Through this test battery we investigated the vestibular ocular reflex pathway (VOR) using caloric test and vHIT and the vestibular cervical reflex pathway (VCR), using cVEMP and vHIT.
Mass sequencing in patient 5 revealed a homozygous R954X mutation in the SH3TC2 gene. The same homozygous mutation was found in 4 other patients (aged 32–80 years) confirming the diagnosis of CMT4C. Disease onset was during childhood in all cases (aged 6–9 years). Two patients in this cohort had been misdiagnosed as FRDA during childhood (Patients 2 and 5). One of them had cerebellar atrophy (reported below). Another had neuralgia symptoms and MRI evidence of thickening of both trigeminal nerves (Table 1). The course of disease was slow in most cases; however patient 1 (age 50) had an aggressive course making him wheel-chair bound much earlier than the other patients in this cohort.
This 80-year-old Swedish woman (Patient 5), born to non-consanguineous parents, had early-onset of unsteadiness and gait difficulties during childhood leading to gradual loss of mobility. She needed a cane at age 50, followed by walker, and became wheelchair-bound by age 60. She developed scoliosis, restrictive pulmonary dysfunction, macular degeneration and sensorineural hearing loss, requiring hearing aids. Her symptoms included numbness, paresthesia with pain and discomfort in both legs, and tongue burning, relieved with gabapentin. Despite these, she had worked part-time in an office. The patient also reported slurred speech and mild dysphagia. On exam, she exhibited leg amyotrophy, foot drop, upper limb and facial myokymia, gaze-evoked and hypermetric saccades mild appendicular dysmetria and dysarthria (Additional file 1: Video). Previously, side-changing nystagmus was documented in her medical records. There was no evidence of spasticity or other pyramidal signs, the limbs were rather flaccid especially the legs. The Montreal Cognitive Assessment score was 26/30. Brain MRI showed atrophy in frontal and parietal brain regions and in the cerebellar hemispheres (Fig. 1a and b). Electroneurography and quantitative sensory testing demonstrated a severe axonal and demyelinating sensorimotor polyneuropathy involving thin sensory fibers. Electromyograpy demonstrated reduction of motor units and myokymia with spontaneous regular rhythmic discharges of motor units in triplets or quadruples in facial muscles. In addition, myokymia activity was recorded in the facial muscles. The vestibular assessment demonstrated a very poor vestibular function compatible with bilateral vestibular areflexia: absence of caloric nystagmus (Fig. 2) or elicitation of dizziness/vertigo upon bithermal caloric irrigation. In addition, the vHIT revealed a very poor gain for the stimulation of the posterior and lateral canals and a depressed but still consistent, response with stimulation of the anterior semicircular canals in both sides. The VOR gain measured with vHIT had an average of 0.29 (Fig. 3). The cVEMP did not demonstrate reproducible responses at two different trails each side (Fig. 4). After excluding FRDA, polyglutamine-related spinocerebellar ataxias, and duplication/deletion in the PMP22 gene, we proceeded with whole exome sequencing, which detected the pathogenic homozygous mutation c.2860C > T (pArg954*, R954X) in SH3TC2. This is the most common CMT4C mutation reported to date [1, 2, 8].
The long disease duration, type of polyneuropathy leading to flaccid ataxia, and absence of systemic features such as cardiomyopathy, diabetes and optic atrophy suggested a diagnostic revision from FRDA in two of five CMT4C patients. While cerebellar atrophy occurs at later stages, an important imaging feature in FRDA is the presence of atrophy and iron accumulation in the dentate nuclei . This is the first report of cerebellar atrophy in CMT4C; however this finding has to be confirmed in larger cohorts.
When polyneuropathy is a predominant initial feature in FRDA, leading to flaccidity, some patients may be misdiagnosed as CMT [10, 11]. However, neurophysiology is helpful to distinguish the sensory ganglionopathy of FRDA from the demyelinating neuropathy of CMT4C. Spasticity is variable in FRDA, becoming more prominent in later stages of the disease (affecting 20% of cases); flaccidity is more common in the atypical forms of the disease, affecting 30–40% of cases . Besides sensory ataxia, other overlapping features for CMT4C and FRDA include scoliosis and hearing loss (Table 2).
Our experience with CMT4C suggests that this entity includes an areflexic, hypotonic FRDA-like phenotype. It is important to note that ataxia has also been reported in other CMT variants, such as X-linked CMTX5  although cerebellar atrophy is otherwise rare in the CMT spectrum. While early features of CMT4C can mimic a flaccid form of FRDA, CMT4C exhibits slower progression, milder cerebellar ataxia, and more severe flaccidity in the legs as a result of severe demyelinating polyneuropathy (Table 2). Another important difference between CMT4C and FRDA are determined by the pattern of abnormal eye movements. Square wave jerks are the most common oculomotor abnormality in FRDA [10,11,12] whereas the presence of nystagmus in CMT4C is rare. Ocular flutter has been reported once in CMT4C . Only a previous study demonstrated subtle vestibulopathy in some patients with CMT4C; however none of those patients had gaze-evoked nystagmus or other features suggesting cerebellar dysfunction . Even though we found evidence of causal or contributory vestibulopathy to explain nystagmus in patient 5, she had other clear cerebellar abnormalities (dysarthria, dysphagia and cerebellar atrophy). Dysmetria in this case is reasonably a manifestation of sensory and cerebellar dysfunction. According to our results on patient 5, a vestibular areflexia is an element of this syndrome. This type of vestibular dysfunction was reported in 7 of 10 Spanish patients with CMT4C . Even though a general depression of vestibular responses occurs with advanced age [18, 19], the very poor vestibular response demonstrated with different modalities is consistent with an underlying bilateral vestibular failure in this patient. Interestingly, a consistent difference in VOR defect for the vertical impulses is observed in our patient, with much more depressed VOR gain in the upward impulses compared with the downward impulses. This vHIT pattern could be the expression of oculomotor disorders associated to a general vestibular failure . Thus, the global vestibular depression is likely due to central dysregulation of oculomotor pathways combined with vestibular insufficiency. Cerebellar ataxia with neuropathy and vestibular areflexia syndrome (CANVAS) is another consideration as a differential diagnosis. However, neither onset during childhood nor hearing loss is part of the CANVAS phenotype . Taken together our findings are of clinical relevance when considering the low prevalence of FRDA in Scandinavia compared to other parts of Europe .
In line with previous findings our data suggest a founder effect for our cohort . An additional novelty in the spectrum of mutations in SH3TC2 is thickening of trigeminal nerves in one CMT4C patient with facial pain. Facial pain has been described before in CMT4C ; furthermore widespread cranial nerve enlargement has been reported otherwise in CMT1A . Expression of SH3TC2 is ubiquitous and includes the cerebellum, but pathological studies to date have focused on peripheral nerves only. Neuropathological brain studies will be needed in order to further define the clinico-anatomical correlations of ataxia and vestibular dysfunction in CMT4C patients.
Availability of data and materials
Charcot-Marie-Tooth disease type 4C
Cervical vestibular evoked myogenic potentials
- SH3TC2 :
SH3 domain and tetratricopeptide repeats 2
Video head impulse test
Piscosquito G, Saveri P, Magri S, et al. Screening for SH3TC2 gene mutations in a series of demyelinating recessive Charcot–Marie–tooth disease (CMT4). J Peripher Nerv Syst. 2016;21:142–9.
Senderek J, Bergmann C, Stendel C, et al. Mutations in a gene encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot–Marie–tooth type 4C neuropathy. Am J Hum Genet. 2003;73:1106–19.
Azzedine H, LeGuern E, Salih MA. Charcot-Marie-tooth neuropathy type 4C. 2008 Mar 31 [Updated 2015 Oct 15]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews®. Seattle: University of Washington, Seattle; 1993-2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1340/
Subramony SH, May W, Lynch D, et al. Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology. 2005;64:1261–2.
Schmitz-Hübsch T, du Montcel ST, Baliko L, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66:1717–20.
Murphy SM, Herrmann DN, McDermott MP, et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-tooth disease. J Peripher Nerv Syst. 2011;16:191–8.
Fife TD, Colebatch JG, Kerber KA, et al. 2nd. Practice guideline: cervical and ocular vestibular evoked myogenic potential testing: report of the guideline development, dissemination, and implementation Subcommittee of the American Academy of neurology. Neurology. 2017;89:2288–96.
Houlden H, Laura M, Ginsberg L, Jungbluth H, Robb SA, Blake J, et al. The phenotype of Charcot-Marie-tooth disease type 4C due to SH3TC2 mutations and possible predisposition to an inflammatory neuropathy. Neuromuscul Disord. 2009;19:264–9.
Ward PGD, Harding IH, Close TG, Corben LA, Delatycki MB, Storey E, et al. Longitudinal evaluation of iron concentration and atrophy in the dentate nuclei in friedreich ataxia. Mov Disord. 2019;34(3):335–43.
Bidichandani SI, Delatycki MB. Friedreich Ataxia. 1998 Dec 18 [Updated 2017 Jun 1]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews®. Seattle: University of Washington, Seattle; 1993–2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1281/
Parkinson MH, Boesch S, Nachbauer W, Mariotti C, Giunti P. Clinical features of Friedreich's ataxia: classical and atypical phenotypes. J Neurochem. 2013;126(Suppl 1):103-17.
Fahey MC, Cremer PD, Aw ST, et al. Vestibular, saccadic and fixation abnormalities in genetically confirmed Friedreich ataxia. Brain. 2008;131:1035–45.
Koeppen AH, Ramirez RL, Becker AB, et al. The pathogenesis of cardiomyopathy in Friedreich ataxia. PLoS One. 2015;10(3):e0116396.
Koeppen AH. Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci. 2011;303(1–2):1–12.
Koeppen AH, Davis AN, Morral JA. The cerebellar component of Friedreich's ataxia. Acta Neuropathol. 2011;122(3):323–30.
Synofzik M, Müller vom Hagen J, Haack TB, Wilhelm C, Lindig T, Beck-Wödl S, et al. X-linked Charcot-Marie-tooth disease, arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence from a family with a novel PRPS1 mutation. Orphanet J Rare Dis. 2014;9:24.
Pérez-Garrigues H, Sivera R, Vílchez JJ, et al. Vestibular impairment in Charcot-Marie-tooth disease type 4C. J Neurol Neurosurg Psychiatry. 2014;85:824–7.
Li C, Layman AJ, Carey JP, Agrawal Y. Epidemiology of vestibular evoked myogenic potentials: data from the BaltimoreLongitudinal study of aging. Clin Neurophysiol. 2015;126:2207–15.
Li C, Layman AJ, Carey JP, et al. Epidemiology of vestibular evoked myogenic potentials: data from the Baltimore longitudinal study of aging. Clin Neurophysiol. 2015;126:2207–15.
Choi JY, Kim HJ, Kim JS. Recent advances in head impulse test findings in central vestibular disorders. Neurology. 2018;90:602–12.
Szmulewicz DJ, Roberts L, McLean CA, et al. Proposed diagnostic criteria for cerebellar ataxia with neuropathy and vestibular areflexia syndrome (CANVAS). Neurol Clin Pract. 2016;6:61–8.
Wedding IM, Kroken M, Henriksen SP, Selmer KK, Fiskerstrand T, Knappskog PM, et al. Friedreich ataxia in Norway - an epidemiological, molecular and clinical study. Orphanet J Rare Dis. 2015;10:108.
Aho TR, Wallace RC, Pitt AM, Sivakumar K. Charcot-Marie-tooth disease: extensive cranial nerve involvement on CT and MR imaging. AJNR Am J Neuroradiol. 2004;25:494–7.
We are grateful to the patients for consenting to this report. We are also grateful to Dr. Peter Gustavsson for valuable advice and to audiologist Ann Ålander for her assistance in the testing of vestibular function.
Martin Paucar’s research is supported by Region Stockholm.
Ethics approval and consent to participate
This study was approved by the local ethics committee in Stockholm. Patients provided oral and written consent to participate.
Consent for publication
Patients provided oral and written consent for publication.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Skott, H., Muntean-Firanescu, C., Samuelsson, K. et al. The cerebellar phenotype of Charcot-Marie-Tooth neuropathy type 4C. cerebellum ataxias 6, 9 (2019). https://doi.org/10.1186/s40673-019-0103-8
- Charcot-Marie-tooth neuropathy type 4C
- Friedreich-like ataxia